Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis

BMC Complementary Medicine and Therapies

Research

Huilian Huang¹  Zhitao Feng²  Xiaolan Shen³  Huirong Qin³  Gao Xiang³  Xiaoqiang Hou⁴  Min Gao⁵ 

[1]Affiliated Renhe Hospital of China Three Gorges University, 443001, Yichang, Hubei, China

[2]Institute of Rheumatology, the First College of Clinical Medical Sciences, China Three Gorges University, 443003, Yichang, Hubei, China

[3]Third-Grade Pharmacological Laboratory On Chinese Medicine Approved By State Administration of Traditional Chinese Medicine, Medical College of China Three Gorges University, 443002, Yichang, Hubei, China

[4]The First College of Clinical Medical Sciences, China Three Gorges University, 443003, Yichang, Hubei, China

[5]The First College of Clinical Medical Sciences, China Three Gorges University, 443003, Yichang, Hubei, China

[6]Institute of Rheumatology, the First College of Clinical Medical Sciences, China Three Gorges University, 443003, Yichang, Hubei, China

[7]Yichuan Community Health Service Center, 200065, Shanghai, China

关键词: Sinomenine;    Traditional Chinese medicine;    Rheumatoid arthritis;    Benefit-risk assessment;    Multicriteria decision analysis;   

DOI  :  10.1186/s12906-023-03864-6

 received in 2022-08-18, accepted in 2023-01-27,  发布年份 2023

来源: Springer

【 摘 要 】

ObjectiveA multicriteria decision analysis (MCDA) model was used to evaluate the benefits and risks of traditional Chinese medicine preparations of sinomenine alone or in combination with conventional drugs in the treatment of rheumatoid arthritis (RA) and to provide a basis for the rational clinical application of sinomenine.MethodsA study search was performed using six major databases, and Review Manager 5.3 was used for data analysis. Then, an MCDA model evaluation system was established for the treatment of RA with sinomenine preparations, and the benefit values, risk values, and total benefit-risk values of sinomenine preparations alone or in combination with conventional drugs were calculated using Hiview 3.2 software. Finally, Monte Carlo simulations were performed using Crystal Ball embedded in Excel software to calculate the 95% confidence intervals (95% CI), and the probability of the differences between the 2 drug regimens was determined to optimize the evaluation results.ResultsForty-four randomized controlled trials (RCTs) were included. Quantitative assessment of the MCDA model showed that the sinomenine preparation alone offered less benefits than when combined with conventional drugs with a benefit difference of 20 (95% CI 3.06, 35.71). However, the risk of the combination was significantly lower with a risk difference of 13(95% CI -10.26, 27.52). The total value of the benefit-risk of sinomenine alone and in combination with conventional drugs was 46 and 53 at 60% and 40% of the benefit-risk ratio of the two dosing regimens, respectively, with a difference of 7 (95% CI -4.26, 22.12). The probability that the comprehensive score of the combined regimen is greater than that of sinomenine alone is 90.1%, and the evaluation was steady.ConclusionThe benefit-risk of the combined application regimen of sinomenine is greater than that of sinomenine alone.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 6

Fig. 1

12302_2023_718_Article_IEq70.gif

Fig. 5

Fig. 4

Fig. 4

Fig. 2